Mutational spectrum of the iduronate-2-sulfatase gene in Mexican patients with Hunter syndrome. 2022

M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
División de Genética, Centro de Investigación Biomédica de Occidente (CIBO), Instituto Mexicano del Seguro Social (IMSS), Guadalajara, Jalisco, México. marthapatriciagallegos08@gmail.com.

Hunter syndrome, or mucopolysaccharidosis type II (MPS II), is caused by deficiency of the lysosomal enzyme iduronate-2-sulfatase (IDS), which is responsible for degrading heparan and dermatan sulfate. The IDS gene is located on chromosome Xq28; pathological variants in this gene mostly consist of missense mutations and small and larger deletions, which produce different phenotypes. However, there is only one record in our population concerning the molecular mechanism of this disease; a genotype-phenotype description is not available. There were included 24 unrelated male patients; clinical features were recorded at a database, fluorometric IDS enzyme activity testing was done for each individual, followed by Sanger sequencing to identify mutations. The mutational spectrum was found in 16 out of 24 Mexican patients with MPS II, and its range of phenotypes was described. The most frequent variants were of the missense type. The most affected exons were exon 3 (c.275T>G, c.284_287del, c.325T>C), exon 8 (c.1035G>C, c.550G>A), exon 9 (c.1403G>C, c.1229_1229del), and exon 7 (c.979A>C; this variant has not been previously reported). Exon 5 (c.438C>T, a non-pathogenic variant) was the least frequent. It was also found that the most severely affected patients were those with large deletions (2 out of 24) [rsaIDS: IDSP1 (P164)x0, FMR1, AFF2 (P164)x2] involving genes and pseudogenes. We found 2 patients with a synonymous mutation in exon 4. Our results confirmed reports in the literature, since the most frequent variants were reported in exons 3 and 8. However, this result varies from one previous report in our population, which mentions large deletions and rearrangements as the most frequent alterations, since complex rearrangements were not found. According to what has been previously found, the most severely affected patients are those in which a whole gene has been deleted.

UI MeSH Term Description Entries

Related Publications

M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
April 2003, Human mutation,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
December 2008, Journal of inherited metabolic disease,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
January 1994, Human mutation,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
November 1993, Human molecular genetics,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
February 1996, Human genetics,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
August 1992, Human molecular genetics,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
February 2006, Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
January 1998, Human mutation,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
January 1995, Human mutation,
M A Ramírez-Hernández, and L E Figuera, and L C Rizo-de la Torre, and M T Magaña-Torres S C Mendoza-Ruvalcaba, and L Arnaud-López, and J E García-Ortiz, and G M Zúñiga-González, and A M Puebla-Pérez, and B C Gómez-Meda, and M P Gallegos-Arreola
January 1995, Human mutation,
Copied contents to your clipboard!